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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.09.031Objectives: Because duration of inotropic support after left ventricular assist device
implantation has been recognized as a surrogate for right ventricular dysfunction, we
sought to (1) identify its preimplantation risk factors, particularly its association
with preimplantation right ventricular dysfunction, and (2) assess its impact on
clinical outcomes.
Methods: Between 1991 and 2002, left ventricular assist devices were implanted in
207 patients, exclusive of those receiving preoperative mechanical circulatory
support, which precluded measuring right ventricular stroke work. Duration of
inotropic support was analyzed as a continuous variable, truncated by death or
transplantation, and in turn as a risk factor for these 2 events.
Results: Inotropic support decreased from 100% on the day of implantation to 57%,
33%, and 22% by days 7, 14, and 21. Its duration was strongly associated with lower
preimplantation right ventricular stroke work index, older age, and nonischemic
cardiomyopathy and was associated (P  .04) with higher mortality before trans-
plantation but not with transition to transplantation. We identified no preimplanta-
tion risk factors for right ventricular assist device use because of its relatively
infrequent use in this population (18 patients, only 4 of whom survived to trans-
plantation).
Conclusion: Duration of inotropic support after left ventricular assist device inser-
tion is strongly correlated with low preimplantation right ventricular stroke work
index. In turn, it was associated with reduced survival to transplantation. Thus, right
ventricular stroke work measured before implantation might be useful in decision
making for biventricular support, destination therapy, or total artificial heart.
Right ventricular dysfunction (RVD) limits the use and effectiveness of leftventricular assist devices (LVADs) as a bridge to transplantation or desti-nation therapy. Identifying the factors anticipating its occurrence is there-
fore of clinical importance. However, RVD is a clinical diagnosis based on syn-
thesizing a number of factors, rather than a single hemodynamic measurement.
Therefore surrogates for RVD have been proposed, but these have limited utility for
preimplantation decision making.
For example, right ventricular assist device (RVAD) support is a surrogate for
severe RVD after LVAD implantation.1-6 Not only is this not known before
implantation, it identifies only the extreme of the RVD spectrum. Our clinical
impression has been that RVD is an underappreciated problem with serious conse-
quences that is more prevalent than reflected by contemporary use of RVAD
support.
Prolonged inotropic support, arbitrarily defined as 14 days or longer, has been
used as another surrogate for less severe forms of RVD.5,6 It also is a postimplan-
The Journal of Thoracic and Cardiovascular Surgery ● Volume 131, Number 2 447
Cardiothoracic Transplantation Schenk et al
TXtation variable; in addition, it has not been explicitly recog-
nized that duration of support is a continuous variable that
might be truncated by transplantation and death. Therefore,
to better manage critically ill patients with clinically evident
RVD and to assist in preimplantation decision making for
biventricular support or cardiac replacement, we reexam-
ined the duration of inotropic support as a surrogate for
RVD by (1) identifying preimplantation factors associated
with it, with particular emphasis on preinsertion right ven-
tricular (RV) stroke work, and (2) assessing its impact on
clinical outcomes.
Patients and Methods
Devices
The study was confined to implantable LVADs: the 1000 IP
HeartMate (1991-1995, n  56), VE HeartMate (1993-2002, n 
105), and Novacor N100 left ventricular assist system (1996-1998,
n  46). Patient selection criteria and management have been
published previously.7
Patients
From December 1991 through July 2002, 259 patients underwent
LVAD implantation at the Cleveland Clinic as a bridge to trans-
plantation. Fifty-two patients on pre-LVAD extracorporeal mem-
brane oxygenation or other temporary mechanical support devices
(eg, Abiomed BVS 5000) were excluded because using these
devices precludes accurately measuring hemodynamic compo-
nents of RV stroke work. Thus, 207 patients were included in this
analysis. During support, patients were maintained on the trans-
plantation list. Demographic, medical history, hemodynamic, and
laboratory values, and outcomes were extracted from our Unified
Transplantation Database, which has been approved for use in
research by the institutional review board (Table 1).
Inotropic Support and RVAD Use
Immediately after LVAD implantation, all patients received ino-
tropes: milrinone, dobutamine, dopamine, or epinephrine, either
alone or in combination. Inotropes were weaned off if LVAD flow
was sufficient under optimal volume loading (2 L · min1 · m2)
and if stable hemodynamics were maintained without them. Pa-
tients were not considered to be on inotropic support if only renal
dose dopamine (3 g · kg1 · min1) was administered.
In 18 patients an RVAD was placed for severe clinically
evident RVD with persistently low LVAD flow despite high-dose
Abbreviations and Acronyms
LVAD  left ventricular assist device
RV  right ventricular
RVAD  right ventricular assist device
RVD  right ventricular dysfunction
RVSWI right ventricular stroke work indexinotropic support.
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Data are summarized as percentages, means  standard deviation,
medians with 15th and 85th percentiles, or 68% confidence limits
equivalent to 1 standard deviation, as appropriate.
Duration of inotropic support. Because duration of inotropic
support might be truncated (censored) by death or transplantation, it
was analyzed from the time of LVAD implantation until the earliest
occurrence of either of these competing events8,9 by using nonpara-
TABLE 1. Characteristics of patients before left ventricular
assist device implantation
Variable n* No. %
Demography
Female sex 207 30 14
Age, y (mean  SD) 207 55  11.1
Body mass index, kg · m2
(mean  SD)
197 27  5.2
Medical history and comorbidity
Ischemic cardiomyopathy 207 127 61
Pre-LVAD hospital stay, d (median
[15th, 85th percentiles])
203 6 (2, 23)
Prior thoracic surgery 207 97 47
Acute myocardial infarction within
3 d before LVAD
207 38 18
Ventricular tachycardia or
fibrillation within 3 d of
implantation
207 74 36
ICD 207 35 17
Preoperative support (within 3 d of
implantation)
Inotropes 194 194 100
IABP 207 157 76
Mechanical ventilation 207 99 48
Hemodynamics
Mean pulmonary artery pressure,
mm Hg (mean  SD)
204 37  8.6
Central venous pressure, mm Hg
(mean  SD)
177 18  6.0
Cardiac index, L · min1 · m2
(mean  SD)
201 1.85  0.52
RVSWI, mm Hg · mL · m2 (median
[15th, 85th percentiles])†
187 390 (190-610)
Laboratory values
Creatinine, mg · dL1 (mean  SD) 206 1.75  0.90
Total bilirubin, mg · dL1 (median
[15th, 85th percentiles])
206 1.4 (0.8, 3.1)
AST, U · L1 (median [15th, 85th
percentiles])
174 45 (22, 200)
SD, Standard deviation; LVAD, left ventricular assist device; ICD, im-
plantable cardioverter-defibrillator; IABP, intra-aortic balloon pump;
RVSWI, right ventricular stroke work index; AST, aspartate
transaminase. *Number of patients for whom data are available. †De-
rived from pulmonary artery catheter monitoring, according to the
following RVSWI  PPA  PCV · SVI, where SVI was derived from
CI/HR (PPA, mean pulmonary artery pressure; PCV, mean central venous
pressure; SVI, stroke volume index; CI, cardiac index; HR, heart rate).metric Kaplan-Meier and parametric hazard function methods. 10
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TXRisk factors for inotropic support and RVAD use. Preopera-
tive risk factors for longer duration of inotropic support were
identified by hazard function regression using variables listed in
the Appendix,10 and for RVAD use by means of logistic regres-
sion. Bootstrap bagging (1000 cycles) was used for risk factor
selection,11 retaining variables in each bootstrap model with a P
value of less than .05. Factors appearing in at least 50% of model
replications were considered reliably identified with a P value of
less than .05.
Of particular importance to this study was pre-LVAD right
ventricular stroke work index (RVSWI). It was calculated from
preimplantation Swan-Ganz catheter data as follows:
RVSWI (Mean pulmonary artery pressure
Mean right atrial pressure) · Stroke volume index
(1)
Impact of inotropic support on clinical outcomes. Associa-
tion of duration of inotropic support with death before transplan-
tation and with transplantation itself was assessed in the context of
a cross-over phenomenon (technically, a modulated renewal pro-
cess).12 Patients were initially considered as being “on inotropes”;
at the time inotropes were discontinued (cross-over), patients were
restarted at a new time zero (“not on inotropes”). A variable for
duration of previous inotropic support was generated whose value
was 0 before inotropic support was discontinued and, thereafter,
number of days of support. This allowed us to quantify the asso-
ciation with outcome of inotropic support and its duration.
To depict the influence of inotropic support on survival, we
used the cross-over model to simulate 6-month survival for a
continuous set of durations of inotropic support. Specifically,
[S(x, I)] · [S (6, NI)] ⁄ [S(x, NI)] (2)
where [S(x, I)] is survival at time x, on inotropes; [S(6, NI)] is
The Journal of Thoracisurvival at 6 months after LVAD implantation, not on inotropes;
and [S(x, NI)] is survival at time x, not on inotropes.
Results
Duration of Inotropic Support
Complete inotropic support information was available in
194 of 207 patients, all of whom were on inotropes after
LVAD implantation. Among patients without RVAD sup-
port (n  176), inotrope use decreased from 100% on the
day of implantation to 57% and 33% by postoperative days
7 and 14, respectively (Figure 1); inotropes were most
frequently discontinued between 3 and 5 days (Figure 1,
inset). Thereafter, decrease of inotropic support became
progressively less steep; 22% remained on inotropes beyond
day 21. No sharp cut-off point for duration of inotropic
support was evident. Of note, 6 (3.4%), 9 (5.1%), and 13
(7.4%) patients without RVADs were censored before days
14, 21, and 28 because of transplantation or death.
Figure 1. Duration of inotropic support af-
ter left ventricular assist device (LVAD)
implantation. Circles represent percent-
ages of patients on inotropic support at
the time after implantation (noted on hor-
izontal axis), vertical bars are asymmetric
68% confidence intervals for these esti-
mates (equivalent to 1 standard error),
and numbers in parentheses are patients
still on inotropes who have not died, un-
dergone transplantation, or had their de-
vice removed after recovery. The solid
line, enclosed within dashed 68% confi-
dence limits, is a parametric estimate;
from this is derived the incidence of end-
ing inotropic support (hazard function)
shown in the inset.
TABLE 2. Preoperative factors associated with longer
duration of inotropic support
Factor Coefficient  SE P value Reliability (%)*
Lower RVSWI† 0.076  0.029 .008 76
Nonischemic
cardiomyopathy
0.51  0.19 .007 51
Older age‡ 0.79  0.34 .02 49
SE, Standard error; RVSWI, right ventricular stroke work index. *Frequency
of appearance in 1000 bootstrap resampling analyses. †Exponential
transformation. ‡Natural logarithmic transformation.
c and Cardiovascular Surgery ● Volume 131, Number 2 449
Cardiothoracic Transplantation Schenk et al
450 The Journal of Thoracic and Cardiovascular Surgery ● Febr
TXRisk Factors for Inotropic Support
Preoperative factors associated with longer duration of ino-
tropic support included lower pre-LVAD RVSWI (P.007,
Table 2 and Figure 2, A). Of patients with an RVSWI of 600
mm Hg · mL · m2 or less, 38% were on inotropes on day
14 compared with 29% and 3% of patients with RVSWIs of
600 to 900 and greater than 900 mm Hg · mL · m2,
respectively (Figure 2, B). The majority of patients on
inotropic support until day 14 had an RVSWI of about 500
mm Hg · mL · m2 or less, but duration of support de-
creased sharply as RVSWI increased (Figure 2, C).
Patients with nonischemic cardiomyopathy, including di-
lated cardiomyopathy, myocarditis, valvar heart disease,
and congenital heart disease, were on inotropic support
longer than those with cardiomyopathy of ischemic cause
(median, 13 vs 7 days; Table 2). Table 3 provides a synopsis
of various median durations of inotropic support associated
with RVSWI, cause of cardiomyopathy, and age. At longer
durations of support, pre-LVAD RVSWI was lower, patient
age was higher, and nonischemic cardiomyopathy was more
common. We found no association between duration of
inotropic support and sex, body mass index, preoperative
central venous pressure, mean pulmonary artery pressure,
pulmonary vascular resistance, and variables reflecting re-
nal and hepatic function.
Impact of Inotropic Support on Clinical Outcomes
A total of 149 patients underwent transplantation, 57 died
before transplantation, and 1 was removed from LVAD
because of recovery. Survival on LVAD support at 30 days,
3 months, and 12 months was 88%, 75%, and 42%, respec-
tively. Risk of death was higher during inotropic support
(P  .006). After inotropic support was discontinued, sub-
sequent risk was higher the longer its duration had been
(P  .04, Figure 3). Figure 4 shows the impact of duration
of inotropic support, derived by simulating the difference in
6-month survival if inotropes were weaned sooner rather
than later. Patients weaned off inotropic support after day 1
had an estimated survival of 72% at 6 months; if inotropic
support continued until days 10, 30, or 60, survival de-
creased to 64%, 57%, and 46%, respectively.
Figure 2. Relation between duration of inotropic support and
preinsertion right ventricular stroke work index (RVSWI). A,
Three-dimensional nomogram. Notice that at high preoperative
RVSWI values, most patients are not on inotropic support beyond
7 days, but at low RVSWI values, patients are more likely to be on
support for a prolonged period. B, Simple and unadjusted strati-
fication of patients according to RVSWI. Format is as for Figure 1.
C, Nomogram as in panel A but solved for prevalence of inotropic
support for at least 14 postoperative (PO) days according to
RVSWI level.
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around 3 months, with 86% of patients undergoing trans-
plantation within 6 months. Rate of transition was unrelated
to duration of inotropic support, suggesting that patients on
inotropes were as likely to undergo heart transplantation as
patients off inotropes.
RVAD Support
An RVAD was placed in 18 (8.7%) patients, 16 within 2
days of LVAD implantation. The other 2 were placed on
days 3 and 12 because of respiratory failure followed by
severe RVD. In 17 of the 18 patients, high-dose inotropic
support for severe RVD preceded RVAD placement. Need
for RVAD support was not related reliably to any preoper-
ative risk factor investigated. Survival before transplanta-
tion of these 18 patients was 47%, 29%, and 22% at 10, 20,
and 30 days, respectively (Figure 5).
Discussion
Principal Findings
Need for inotropic support decreased steadily and continu-
ously after LVAD implantation, although some patients
remained on inotropic support for several weeks. Duration
of inotropic support was strongly associated with pre-
LVAD RVSWI and was, in turn, associated with increased
risk of death before transplantation, although not with ear-
lier transplantation.
Clinical Correlates of RVD after LVAD Implantation
Several studies have used clinical surrogates of RVD after
LVAD implantation, particularly need for RVAD or inotro-
pic support.3,5,6,13 Need for RVAD support identifies pa-
tients with severe RVD, which is often fatal. We have
previously shown an association between poor preoperative
RV contractility and subsequent RVAD implantation. In
this study we did not find an association between RVAD use
and preoperative factors. However, this apparent discrep-
ancy is explained by our excluding 52 patients with pre-
LVAD temporary mechanical circulatory assistance, which
was a risk factor for RVD in prior studies.2,14,15 We ex-
TABLE 3. Duration of inotropic support and associated fac
Inotropic support
duration (d)
n*
RVSWI
(mm Hg · mL · m
Median Range Mean  SD
3 1-5 71 470  270
7 6-9 38 400  220
14 10-20 48 370  200
27 21-45 26 360  170
69 46-185 11 390  210
RVSWI, Right ventricular stroke work index; SD, standard deviation. *Numcluded these patients because pre-LVAD hemodynamic
The Journal of Thoracimeasurements (and specifically RVSWI) with transiently
turned off mechanical support were not available in many
cases.
We believe that use of inotropic support as a surrogate
for less severe RVD requires a more sophisticated approach
than simply dichotomizing its duration into short versus
long support, as has been done by others.5,6,16 Its duration is
a continuous variable without a sharp cut-off point with
respect to outcomes. Consider the limitations of any arbi-
trary cut-off duration. With a cut-off duration of 14 days, a
patient on inotropic support for 13 days would be classified
as not having RVD, whereas one supported for 14 days
would be classified as having RVD. This is not a clinically
helpful distinction.
Clinical Implications
Factors associated with prolonged inotropic support identify
patients at risk for RVD, delayed rehabilitation, and other
complications after LVAD implantation. Although high pre-
operative pulmonary vascular resistance is a well-recognized
risk factor for RVD after heart transplantation17 and thus
serves as an exclusion criterion, a preoperative predictor of
RVD after LVAD implantation useful for decision making
has yet to be established. Our results suggest that preoper-
ative RV contractility as reflected in RVSWI, but not pre-
load or afterload, might be one such factor. We now rou-
tinely measure RVSWI to assess RV contractility. Perhaps
RVSWI will be measured and manipulated as we do pul-
monary vascular resistance to assess transplant candidacy.
Ideally, a more load-independent measure than RVSWI will
be identified to quantify RV contractility. We speculate that
such a measure could allow us to better anticipate need for
biventricular support versus LVAD support alone.
Current clinical strategies for treating RVD focus on
increasing RV contractility with inotropes, providing circu-
latory support only in cases of severe RVD. For example,
we use milrinone, a phosphodiesterase III inhibitor with
positive inotropic and vasodilatory effects.18 Nevertheless,
as found in this study, pharmacologic treatment of RVD is
Age (y)
Ischemic
cardiomyopathy
an Mean  SD Median No. %
55  11 57 50 70
51  12 51 26 68
57  11 58 23 48
58  9.6 59 13 50
55  10 60 5 45
f patients for whom RVSWI data were available.tors
2)
Medi
450
315
338
368
433associated with poor survival and thus requires alternative
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high mortality, this likely reflects current indications. If
RVADs were used for less severe forms of RVD, their benefit
might become more apparent. Unfortunately, current RVAD
use is associated with high risks of bleeding and thromboem-
bolic events, which preclude broader clinical application. Thus,
developing blood-compatible implantable RVADs is needed.
Cardiac replacement with total artificial hearts might become
Figure 3. Impact of inotropic support on survival during left
ventricular assist device (LVAD) support. A, Hazard functions
(instantaneous risk of death) for 2 simulated patients. Patient A
was weaned off inotropic support 4 days after LVAD implantation.
Hazard decreased nearly 10-fold. Patient B was weaned off
inotropic support 21 days after LVAD implantation. Hazard de-
creased but not as much as for patient A. B, Survival effect of
short (simulated patient A) versus prolonged (simulated patient B)
inotropic support derived from the hazard functions. Compared
with patient A, survival of patient B is reduced both by longer
exposure to the same high hazard during inotropic support and by
higher hazard after discontinuing inotropic support commensu-
rate with its longer duration.an alternative for biventricular failure.19,20 Results pre-
452 The Journal of Thoracic and Cardiovascular Surgery ● Febrsented in this report should be helpful in selecting candi-
dates for these devices.
The most practical use of the knowledge from this study
might be in decision making for destination therapy with
LVADs alone. If patients remain inotrope dependent, their
prognosis is predicted to be poor in the absence of a bio-
compatible RVAD or other treatment option.15 As demon-
strated from this study, nonischemic cardiomyopathy, ad-
vanced age (likely a large group of these will not be
transplantation candidates), and poor preoperative RV func-
tion with low RVSWI might prove to be relative clinical
contraindications to destination therapy with LVADs.
Figure 4. Simulated 6-month survival according to duration of
inotropic support expressed on vertical axis as percentage of
patients surviving to transplantation. See the “Patients and
Methods” section, equation (1), for details of calculation.
Figure 5. Survival after implantation of a right ventricular assist
device (RVAD). Format is as in Figure 1.
uary 2006
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Duration of post-LVAD inotropic support is a recognized
surrogate for RVD. Patients might have poor RV function
by echocardiography, yet adequate LVAD flow without
inotropic support. Unlike others, however, we have consid-
ered duration of inotropic support as a continuous variable.
A drawback to its use as a surrogate for RVD (either as a
dichotomous or continuous variable) is that it is truncated
(censored) by both death before transplantation and trans-
plantation itself. We have overcome this problem by (1) use
of time-related (censored data) methods and (2) formulation
of the data in the fashion of competing risks.9 Nevertheless,
only 7.4% of patients without RVADs were censored by one
of these competing events within the first postoperative
month. Note that these patients might not have been cate-
gorized as having RVD if an arbitrary duration of inotropic
support were used to define it, even if they were on high-
dose support and had a poorly contracting right ventricle at
the time of early transplantation or death. Thus, we contend
that analysis of inotropic support should be time related,
with consideration of competing risks.
In identifying risk factors for duration of inotropic sup-
port, we considered only preimplantation variables. Cer-
tainly, postoperative complications, such as pump malfunc-
tion, could also result in need for inotropic support. In
addition, many surgeons wean inotropes after LVAD im-
plantation according to device flow and central venous
pressure. These postoperative variables were deliberately
not considered because our objective was to identify pre-
implantation risk factors that might help guide device selec-
tion. We also did not examine time-varying dosage of inotropic
support as a longitudinal end point, only its duration.
Finally, patients receiving pre-LVAD temporary me-
chanical circulatory support were excluded from this study
to ensure accurate assessment of hemodynamics. For this
reason, we were limited in some aspects of our analyses that
have been covered adequately in our previous studies.3,7
Thus, we recognize that pre-LVAD circulatory support is
associated with occurrence of severe post-LVAD RVD
(need for RVAD), even though we could not reanalyze this
in the present study. In our experience, these patients also
have preoperative RVD and likely have a low RVSWI, if it
could be measured accurately.
Conclusion
Duration of inotropic support is a valuable surrogate of
RVD after LVAD insertion because of its strong association
with death before transplantation. However, this relation to
clinical outcome is continuous, with no sharp break point,
and therefore we recommend abandoning arbitrary dura-
tions, such as 14 days, in favor of this continuous relation.
Importantly, low pre-LVAD RVSWI is strongly associated
with longer duration of inotropic support. Therefore, mea-
The Journal of Thoracisuring preimplantation RVSWI prospectively might be
helpful in selecting candidates more appropriate for biven-
tricular and total artificial heart support than for destination
therapy with LVADs.
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Appendix
Preoperative variables considered in analyses Demog-
raphy: Age (y), sex, body surface area (m2), body mass
index (kg · m2), weight (kg), height (cm).
Medical history: Diagnosis of heart disease, prior thoracic
surgery, presence of implantable cardioverter-defibrillator.
454 The Journal of Thoracic and Cardiovascular Surgery ● FebrTemporary support (within 3 days of implantation): Mechani-
cal ventilation, intra-aortic balloon pump use, inotropic support,
duration of pre-LVAD hospital stay (d).
Comorbidities (within 3 days of implantation): Acute myocar-
dial infarction, infection, ventricular tachycardia or fibrillation.
Hemodynamics (immediately before implantation): Pulmonary
artery systolic, diastolic, and mean pressures (mm Hg), cardiac
index (L · min1 · m2), pulmonary vascular resistance (Wood
units), central venous pressure (mm Hg), right ventricular stroke
work index (mm Hg · mL · m2) calculated from pulmonary artery
(Swan-Ganz) data as follows:
RVSWI (Mean pulmonary artery pressure
Mean right atrial pressure) · Stroke volume index.
Laboratory values (1 day before implantation): Creatinine (mg ·
dL1), total bilirubin (mg · dL1), aspartate transaminase (U · L1),
total protein (g · dL1), albumin (g · dL1).
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